Table 13. Half-width confidence interval summary* for select vaccines, NIS-Teen, 2016-2017

	All Estimation Areas Including Territories				All Estimation Areas Excluding Territories			
	2016		2017		2016		2017	
	Mean	Median	Mean	Median	Mean	Median	Mean	Median
≥ 1 dose Tetanus, diphtheria, and acellular pertussis (Tdap)	1.50	1.50	1.34	1.30	1.50	1.50	1.27	1.30
≥ 1 dose Human papillomavirus (HPV) vaccine	2.39	2.40	2.19	2.10	2.41	2.40	2.14	2.10
≥ 1 dose Meningococcal conjugate (MenACWY)	1.77	1.80	1.60	1.60	1.76	1.80	1.54	1.60
UTD † HPV among adolescents 13-17 years (All adolescents)	2.39	2.35	2.27	2.10	2.40	2.40	2.24	2.10
UTD HPV among adolescents 13-17 years (Females)	3.34	3.30	3.26	3.20	3.37	3.30	3.23	3.15
UTD HPV among adolescents 13-17 years (Males)	3.25	3.25	3.02	2.80	3.25	3.20	2.96	2.80

Abbreviations: HPV = human papillomavirus vaccine; MenACWY = quadrivalent meningococcal conjugate vaccine; Tdap = tetanus, diphtheria, and pertussis vaccine.

^{*} Half-width confidence interval for the difference between single- and dual-frame estimates for a given year and vaccine.

[†] UTD HPV includes those with \geq 3 doses, and those with 2 doses when the first HPV vaccine dose was initiated prior to age 15 years and there was at least five months minus four days between the first and second dose. This update to the HPV recommendation occurred in December of 2016.